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Abstract
We previously reported that posttransplant alloantibody production in CD8-deficient hosts is 
IL-4+CD4+ T cell-dependent and IgG1 isotype-dominant. The current studies investigated the 
hypothesis that IL-4-producing NKT cells contribute to maximal alloantibody production. To 
investigate this, alloantibody levels were examined in CD8-deficient wild-type, CD1d KO and 
Jα18 KO transplant recipients. We found that the magnitude of IgG1 alloantibody production was 
critically dependent on the presence of type I NKT cells, which are activated by day 1 
posttransplant. Unexpectedly, type I NKT cell contribution to enhanced IgG1 alloantibody levels 
was IFN-γ-dependent and IL-4-independent. Cognate interactions between Type I NKT and B 
cells alone do not stimulate alloantibody production. Instead, NKT cells appear to enhance 
maturation of IL-4+CD4+ T cells. To our knowledge, this is the first report to substantiate a critical 
role for type I NKT cells in enhancing in vivo antibody production in response to endogenous 
antigenic stimuli.
Introduction
Alloantibodies play a critical role in acute and chronic rejection after transplantation (1, 2). 
Acute antibody-mediated rejection is associated with worse graft outcome than T cell-
mediated rejection (3). This suggests that conventional agents, targeting T cells (4, 5), 
suboptimally prevent the development or pathogenicity of alloantibody on allograft function 
and survival. Many factors have the potential to impact humoral alloimmunity after 
transplantation. Recipient and donor genetics impact the degree and specificity of 
alloantigen disparity (6-8), and influence the repertoire of cellular, cytokine and other 
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factors which contribute to the resulting immune response (9, 10). The cells or organ to be 
transplanted determine the antigen load and expression of MHC and other molecules 
impacting the humoral immune responses evoked. Additionally, the site where the cells or 
organs are transplanted determines local microenvironmental factors such as resident cell 
populations, lymph nodes, and vasculature (11). Despite the importance of humoral 
alloimmunity in clinical transplantation, mechanisms mediating posttransplant alloantibody 
production and regulation are complex and not well understood.
A conceptual barrier to progress in understanding mechanisms regulating posttransplant 
humoral alloimmunity is the conventional focus on CD4+ T cells as the dominant cell 
population influencing B cell antibody responses (12, 13). Using a well characterized in vivo 
model of posttransplant alloantibody production, we provided first evidence supporting a 
pivotal role for IFN-γ+CD8+ T cells in the inhibition of posttransplant IgG1 (IL-4-
dependent) alloantibody production, in part, by downregulating the development of 
IL-4+CD4+ T cells (14) and, in part, by killing IgG1+ B cells (15). Our data raise the 
possibility that current agents suppress T cell immune pathways which both promote (CD4+ 
T cells) and downregulate (CD8+ T cells) alloantibody production. In addition, other cells 
may be important mediators of alloantibody formation that are not currently targeted by 
current immunosuppressive therapies.
In our model, the IgG1 alloantibody generated is non-complement fixing and mediates 
antibody-dependent cell-mediated hepatocellular toxicity (ADCC). Our in vitro studies 
found that ADCC was mediated by macrophages, which was confirmed through in vivo 
studies where we found that survival of hepatocellular allografts was significantly prolonged 
in macrophage-deficient recipients, even in the presence of significant amounts of serum 
alloantibody (16). Studies by others also demonstrate a role for IgG1 in the induction of 
ADCC cytotoxicity and macrophage-mediated phagocytosis through FcγRIII (17-19).
Preliminary observations in our lab showing reduced alloantibody levels in CD8-depleted 
CD1d KO recipients suggested a novel role for NKT cells in promoting posttransplant 
alloantibody production. NKT cells, consisting of type I and type II NKT cell subsets, have 
a T cell receptor (TCR) that is activated by (glycol)lipid antigens presented through CD1d 
(20). CD1d, a MHC-like complex, is expressed on antigen presenting cells including 
dendritic cells, B cells and macrophages (21). Following type I NKT TCR binding to 
glycolipid antigen and CD1d, activated type I NKT cells can play an important role in the 
activation and regulation of multiple immune cells subsets including NK, T, and B cells 
(22-26). NKT cells have pleiotropic functions heavily influenced by microenvironmental 
factors (27). Type I NKT cells tend to be proinflammatory while type II NKT cells are anti-
inflammatory and can downregulate type I NKT cells, as can T regulatory cells (28). While 
CD1d is identified as the dominant trigger for NKT cell activation, in some circumstances 
NKG2D may activate NKT cell function through interaction with RAE1, a MHC I like 
molecule (29). Of particular interest, it has been shown that type I NKT cells can induce 
antibody production in response to exogenous protein antigens in conjunction with α-
Galactosylceramide (α-GalCer; the canonical CD1d ligand that stimulates type I NKT cells) 
(25, 26, 30-33). Type I NKT cells produce a variety of pro- and anti-inflammatory cytokines 
(IFN-γ, IL-4, IL-6, IL-13, etc.) and chemokines (RANTES, CCL22, CCL3, CCL4) (34). We 
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therefore hypothesized that type I NKT cells, without the requirement for exogenous NKT 
cell antigens or ligands, contribute to enhanced posttransplant IgG1 alloantibody levels 
through the production of IL-4 and perhaps other Th2 like cytokines which promote CD4+ T 
cell maturation. However, our hypothesis proved to be incorrect since we unexpectedly 
found that IFN-γ+NKT (and not IL-4+NKT) cells are necessary to enhance the magnitude of 
alloantibody production in our model.
Materials and Methods
Experimental animals
FVB/N (H-2q MHC haplotype, Taconic), C57BL/6 (wild-type; WT), and CD8 KO (both 
H-2b, Jackson Labs) mouse strains (all 6-10 weeks of age) were used in this study. Jα18 KO 
mice (35) and CD1d KO mice (36) (H-2b, both backcrossed >8 times onto a C57BL/6 
background) were provided to Dr. Randy Brutkiewicz by Dr. Luc van Kaer (Vanderbilt 
University, Nashville, TN) with permission (for the Jα18 KO mice) from Dr. Masaru 
Taniguchi (Chiba University, Chiba, Japan). Transgenic FVB/N mice expressing human α-1 
antitrypsin (hA1AT) were the source of “donor” hepatocytes, as previously described (37). 
All experiments were performed in compliance with the guidelines of the IACUC of The 
Ohio State University (Protocol 2008A0068-R1).
Hepatocyte isolation, purification, and transplantation
. Hepatocyte isolation and purification was completed, as previously described (37), by 
perfusing the liver with a 0.09% EGTA-containing calcium-free solution. The liver was then 
perfused with a 0.05% collagenase (type IV; Sigma Aldrich, St. Louis, MO) in 1% albumin. 
Liver tissue was minced, filtered, and washed with RPMI 1640 containing 10% FBS. 
Hepatocytes were purified on a 50% Percoll gradient (Sigma Aldrich). Hepatocyte viability 
and purity was consistently >95%. Donor FVB/N hepatocytes (2×106) were transplanted by 
intrasplenic injection with circulation of donor hepatocytes to the host liver, as previously 
described (37). Graft survival was determined by detection of secreted hA1AT in serial 
recipient serum samples by ELISA (37, 38). The reporter protein hA1AT does not elicit an 
immune response since syngeneic, hA1AT-expressing hepatocytes survive long term (37).
CD8+ T cell depletion
Recipients were depleted of circulating CD8+ T cells, by intraperitoneal (i.p.) injection of 
100 μg of mAb (clone 53.6.72; day -2,-1), as described (14). Depletion was confirmed 
through flow cytometric analysis of recipient peripheral blood lymphocytes.
Type I NKT cells isolation and purification
Type I NKTs were isolated from liver mononuclear cells (LMNCs) obtained from syngeneic 
C57BL/6 mice. LMNC isolation was performed as described (39). In brief, the liver was 
perfused with PBS. Liver tissue was minced, filtered, and washed with PBS (2% FBS, 
0.02% sodium azide). LMNCs were purified by a 33.75% Percoll gradient. Type I NKT cell 
staining and sorting was performed as described (40). Briefly, isolated LMNCs were Fc 
receptor blocked (2.42G hybridoma supernatant), washed, and with PBS-57-loaded APC-
conjugated CD1d tetramers (1:2000; NIH NIAID Tetramer Facility, Emory University 
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Vaccine Center, Atlanta, GA). Additional samples of LMNCs were unstained or stained 
with unloaded APC-conjugated CD1d tetramers (1:2000) for flow cytometric gating 
purposes. Cells were sorted at The Ohio State University Comprehensive Cancer Center's 
Flow Cytometry Core Laboratory using FACSAria (Becton Dickinson, Franklin Lake, NJ). 
PBS-57-loaded CD1d positive cells represented the type I NKT cell population. In general, 
this method yielded approximately 3 million LMNC's per liver. LMNC's ranged from 
10%-30% tetramer positive type I NKTs. Type I NKT cells (>98% pure) were pooled from 
multiple mice for AT.
ELISPOT
Analysis of B cells for IgG1 production by ELISPOT was performed as previously 
described (41). Plates were analyzed by computer-assisted image analysis using a KS 
ELISPOT Automated Reader with KS ELISPOT software 4.2 (Carl Zeiss Inc, Thornwood, 
NY). The data are reported as the number of relative Spot Forming Cells (SFC) per 1x106 
splenocytes. A side-by-side ELISA was run in a similar fashion and performed as previously 
described (42). Colormetric analysis was utilized to quantitate in vitro antibody production 
by a Spectramax Plus microplate reader (Molecular Devices, Sunnyvale, CA).
Assay of allospecific antibody
Recipient serum was tested for allospecificity first by incubation with allogeneic FVB/N 
target splenocytes, as previously described (14). The percent binding of total IgG to 
splenocyte targets was determined by a second incubation with FITC-conjugated goat anti-
mouse IgG Fc (Organon Teknika, Durham, NC) and analysis by flow cytometry. 
Alloantibody level is represented as the percentage of target cells labeled by secondary 
fluorescent antibody as described previously (12). Total alloantibody and isotype titering- 
To quantitate alloantibody titer, we reanalyzed the recipient serum, using published methods 
(43). Briefly, serum was serially diluted and incubated with allogeneic FVB/N target 
splenocytes. Splenocytes were then stained with FITC-conjugated goat anti-mouse IgG Fc 
or IgG isotypes (IgG1, IgG2b, IgG2c, IgG3; Bio-Rad Laboratories, Hercules, CA). The 
mean channel fluorescence was measured for each sample and the dilution that returned the 
mean channel fluorescence observed when the splenocytes were stained with the 1:4 dilution 
of naïve C57BL/6 serum was divided by two and recorded as the titer.
Intracellular cytokine staining
Splenocytes were isolated from transplant recipients (day 7) and incubated with Leukocyte 
Activation Cocktail (Becton Dickinson). Splenocytes were treated with anti-FcγR mAb and 
subsequently stained with anti-CD4 mAb (clone GK1.5; Becton Dickinson) and PBS-57-
loaded APC-conjugated CD1d tetramers. Intracellular staining was performed following 
eBiosciences recommendations for IFN-γ (XMG1.2) and IL-4 (11B11; both Becton 
Dickinson). CD4+NKT− T cells were utilized for gating.
Statistical analysis
General linear models were fit for each outcome and contrasts were used to compare 
relevant groups to test the primary hypothesis/hypotheses in each experiment. Model 
Zimmerer et al. Page 4
Am J Transplant. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
assumptions were assessed and violations to the normality assumption were addressed by 
transforming the data to the natural log scale. Where log transformations did not resolve the 
violation of the normally distributed residuals assumption, non-parametric hypothesis testing 
using the Wilcoxon rank-sum test were conducted (Figure 1B and 3B). In cases where 
multiple group testing is conducted for an outcome, the overall type 1 error rate was 
maintained at 5% using Holm's step-down procedure to adjust for multiple comparisons. All 
analyses were conducted using SAS Statistical Software Version 9.3 (SAS Institute, Inc., 
Cary, NC). Summary statistics are listed as the mean plus or minus the standard error.
Results
Type I NKT cells significantly contribute to the magnitude of alloantibody production 
posttransplant
We previously reported that CD8-deficient transplant recipients are high IgG1 alloantibody 
producers which is IL-4-dependent (no antibody was detected in CD8-depleted IL-4 KO 
recipients). AT of WT (IL-4+) CD4+ T cells into CD8-depleted IL-4 KO mice restored 
alloantibody production but not to levels expected in CD8-depleted WT recipients (14). This 
suggests that other IL-4+ cells are required for high alloantibody production. To determine if 
NKT cells, known strong producers of IL-4 (20), contribute to maximal alloantibody in 
CD8-deficient high alloantibody producers, CD1d KO recipients [NKT-deficient; (36)] were 
CD8-depleted (day -2,-1 with respect to transplant) and transplanted with allogeneic 
hepatocytes. Serum samples were collected to measure alloantibody (by two methods- 
percent allogeneic target splenocytes bound and by serum dilution to calculate alloantibody 
titer). We found day 14 alloantibody levels were significantly reduced in CD8-depleted 
CD1d KO (34.8±4.0%; titer=333±39) compared to CD8-depleted WT recipients 
(76.9±3.4%; titer=1,800±89; Figure 1A, 1B) on day 14 posttransplant. Despite alloantibody 
reduction in CD8-depleted CD1d KO recipients, rejection was not delayed (MST= day 14) 
compared to CD8-deficient WT (MST= day 14) or CD8-sufficient CD1d KO recipients 
(MST= day 10; p>0.05 ns for both). To determine if a deficiency in type I NKT cells was 
responsible for reduced alloantibody levels, we performed similar experiments utilizing 
Jα18 KO (type I NKT cell-deficient) recipients. Serum alloantibody levels in CD8-depleted 
Jα18 KO recipients (6.6±2.4%; titer=22±2) were markedly reduced compared to CD8-
depleted WT recipients (76.9±3.4%; titer=1,800±89) and CD8-depleted CD1d KO recipients 
(34.8±4.0%; titer=333±39). This reduction in alloantibody was accompanied by delayed 
allograft rejection in CD8-deficient Jα18 KO recipients (MST= day 17) compared to CD8-
sufficient Jα18 KO recipients (MST= day 10; p<0.001). Serial analysis of alloantibody 
levels in CD8-depleted WT and Jα18 KO recipients showed both exhibited peak circulating 
alloantibody levels on day 14-21 posttransplant (data not shown), consistent with our 
previous studies (14). Therefore, the difference in quantity of alloantibody between the two 
groups is not due to a difference in the kinetics of alloantibody production. Additionally, as 
previously reported (14), alloantibody isotype is IgG1-dominant with minimal contribution 
of IgG2b, IgG2c, and IgG3 (Figure 1C).
To determine if the higher magnitude of alloantibody produced in type I NKT cell-sufficient 
recipients was due to higher numbers of antibody-producing B cells (versus higher 
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production of antibody per B cell), we analyzed the number of B cells that produced IgG1 
antibody within WT and Jα18 KO recipient splenocytes by ELISPOT on days 4, 8, 11, and 
15 posttransplant. CD8-depleted WT recipient splenocytes exhibited significantly more 
IgG1-producing cells (spot forming cells, SFC) per 106 cells analyzed on days 8 (288±42) 
and 11 (266±53) posttransplant compared to naïve WT mice (45±15; Figure 2). CD8-
depleted Jα18 KO recipient splenocytes exhibited significantly reduced numbers of IgG1-
producing cells per 106 cells on day 8 (169±28) and 11 (94±30) posttransplant compared to 
CD8-depleted WT recipient splenocytes. Notably, splenocytes from Jα18 KO and WT 
recipients have similar numbers of B cells (B220+; 41.1±3.5% versus 39.1±7.5%, 
respectively; p>0.05). Although not quantitative, the magnitude of IgG1 produced per B 
cell, determined by spot size, was similar between WT and Jα18 KO recipients, suggesting 
that B cells from both groups secreted similar amounts of IgG1 (data not shown). The 
significant difference in the number of IgG1-producing cells between CD8-deficient WT 
and Jα18 KO recipients strongly suggests NKTs play a critical role in enhancing alloprimed 
B cell activation and/or maturation.
Type I NKT cell-enhancement of IgG1 isotype-dominant alloantibody production is IFN-γ-
(but not IL-4-)dependent
AT studies were used to definitively establish an in vivo role for type I NKT cells in 
enhancing alloantibody production. Type I NKTs were transferred (1×106 cells i.v.) into 
CD8-depleted Jα18 KO mice immediately following allogeneic hepatocyte transplant, and 
serum samples collected for the measurement of alloantibody levels. We found AT of WT 
NKTs into CD8-depleted Jα18 KO recipients (33.3±1.7%; titer=142±11) significantly 
enhanced alloantibody production compared to control CD8-depleted Jα18 KO recipients 
(6.6±2.4%; titer=22±2; Figure 3A, 3B). AT of NKTs resulted in increased alloantibody 
production and faster allograft rejection in CD8-depleted Jα18 KO recipients (MST= day 
10) compared to CD8-depleted Jα18 KO recipients without AT (MST= day 17; p<0.05). To 
determine whether type I NKTs required IL-4 to promote alloantibody production, Jα18 KO 
recipients received AT of IL-4-deficient (IL-4 KO) or WT NKTs. Surprisingly, IL-4-
deficient NKTs (27.0±2.1%; titer=113±16) were equally capable of enhancing 
posttransplant alloantibody levels as WT NKTs. Contrastingly, IFN-γ-deficient (IFN-γ KO) 
NKTs did not enhance alloantibody production in Jα18 KO recipients (4.8±2.3%; 
titer=18±1). Alloantibody isotype is IgG1-dominant in Jα18 KO recipients AT’ed with WT 
or IL-4 KO type I NKTs with minimal contribution of IgG2b, IgG2c, and IgG3 (Figure 3C). 
Type I NKTs upregulated intracellular IL-4 and IFN-γ by flow cytometry as early as day 1 
posttransplant (data not shown). These results support the conclusion that type I NKTs 
enhance posttransplant IgG1 alloantibody production in an IFN-γ-dependent (but IL-4-
independent) manner.
Enhanced number of IL-4+CD4+ T cells in NKT-sufficient high alloantibody producers
To determine if NKT cell cognate interactions with B cells are sufficient to induce 
alloantibody production, we utilized MHC II KO recipients which are CD4+ T cell-deficient. 
While others have reported that NKTs facilitate antigen-specific antibody production in 
MHC II KO mice in response to viral immunization (33), neither MHC II KO nor CD8-
depleted MHC II KO recipients developed alloantibody posttransplant (Figure S1). Because 
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NKTs alone are insufficient to drive alloantibody production by B cells in our model, we 
hypothesized that NKTs drive the maturation of IL-4+CD4+ T cells. To address this 
hypothesis, CD4+ T cells from CD8-depleted WT and CD8-depleted CD1d KO recipient 
mice were evaluated on day 7 for intracellular IFN-γ or IL-4 expression (no significant 
difference in splenocyte numbers between CD1d KO and WT recipients). Of note, CD4+ 
type I NKTs constitute approximately 0.5% of all CD4+ T cells within the spleen and less 
than 0.1% of all IL-4+ and IFN-γ+ CD4+ T cells (data not shown). WT recipients exhibited a 
similar percentage of IFN-γ+CD4+ T cells (5.0%±0.4%) and IL-4+CD4+ T cells (1.1%
±0.3%) compared to CD1d KO recipients (IFN-γ+CD4+ T cells= 5.6%±0.5%, IL-4+CD4+ T 
cells= 1.5%±0.3%; Figure 4; representative data shown in Figure S2). In contrast, CD8-
depleted CD1d KO recipients exhibited significantly fewer IL-4+CD4+ T cells (1.5%±0.2%) 
(and similar numbers of IFN-γ+CD4+ T cells, 4.3%±0.2%) compared to CD8-depleted WT 
recipients (IL-4+CD4+ T cells= 2.6%±0.2% and IFN-γ+CD4+ T cells= 5.2%±0.4%). This 
suggests that NKTs drive the maturation and/or proliferation of Th2 IL-4+CD4+ T cells.
Discussion
Preliminary studies in our well characterized transplant model suggested that cells other than 
CD4+ T cells and B cells might be critical for maximal IgG1 alloantibody production. We 
and others have shown that depletion of CD8+ T cells significantly increased antigen-
specific antibody production in allergy, bacterial infection, viral infection, and platelet 
transfusion (15, 44-52). We reported a dominance of IgG1 alloantibody produced in CD8-
deficient recipients (14) (confirmed in the current studies) but which differ from a report by 
Sayeh et al. which found an increase in IgG2a following CD8-depletion (53). This may be 
attributable to differences in the antigenic stimuli and other experimental conditions 
(repeated antigenic stimuli of five platelet infusions over five weeks). Interestingly, they 
reported increased IL-4 levels (expected to drive IgG1 production) in these CD8-depleted 
recipients.
In the current study, we found that IgG1 alloantibody levels in CD8-deficient recipients 
were reduced in the absence of CD1d or type I NKT cells. Furthermore, AT of type I NKT 
cells enhanced IgG1 alloantibody levels (and allograft rejection) in NKT cell-deficient 
recipients in an IFN-γ-dependent, IL-4-independent manner. This study provides the first 
evidence that type I NKT cells, responding to endogenous signals/stimuli, significantly 
contribute to IgG1 alloantibody production posttransplant. Reports by others also show a 
role for NKT cells in antibody production. However, the majority of these reports have 
occurred in the context of NKT cell activation by exogenous administration of α-GalCer 
(25, 26, 30-33, 54, 55) or other exogenous glycolipids including OCH (56), which is a 
glycolipid known to skew conditions toward Th2 conditions (57). Thus, another novel 
aspect of the current study is NKT-mediated enhancement of in vivo antibody production 
without concurrent exogenous glycolipid administration to activate NKT cells.
There are some aspects of the animal models used in this study which require consideration 
for interpretation of our data. Figure 1 shows that Jα18 KO recipients produce less antibody 
than the CD1d KO recipients which might be due to altered TCR repertoire diversity in Jα18 
KO mice (58). In addition, Jα18 KO recipients have inhibitory type II NKT cells (59) which 
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may downregulate antibody production, in contrast to CD1d KO recipients that lack all NKT 
cells. Nevertheless, AT studies clearly support that type I NKT cells significantly enhance 
alloantibody production posttransplant (though not to the levels observed in WT recipients). 
The lower levels may be due to the limited number of NKT cells transferred. However, 
increasing the number of type I NKT cells for AT (2×106) did not result in further 
enhancement of posttransplant alloantibody levels (data not shown). While impairment of in 
vivo trafficking may limit the availability of AT'ed type I NKT cells, previous reports (60), 
as well as our unpublished data, suggest that the majority of transferred immune cells do 
indeed traffic to the liver, spleen, and lymphoid tissue.
NKT cells may enhance antibody production through direct interaction with B cells or 
indirectly, by stimulating non-B cell APCs (e.g., DCs) and CD4+ T cell activation (25, 26, 
30-33). We know from previous studies that alloantibody production in our model is IL-4-
dependent and IL-4+CD4+ T cells drive IgG1 alloantibody production (14). In AT studies 
we have demonstrated that alloantibody in this model is detrimental to graft survival, since 
AT of alloantibody into immunodeficient SCID hepatocyte recipients prompts rejection 
within 7 days (44). Furthermore our published in vitro and in vivo studies demonstrate that 
alloantibody-mediated parenchymal cell rejection is mediated by macrophages (16).
The role of specific alloantibody isotypes in graft rejection or tolerance is complex and 
likely influenced by many recipient and donor factors. For example, in alignment with our 
results showing a detrimental role for IgG1 alloantibody are results from Hirohashi et al. 
who reported that IgG1 alloantibody triggers chronic arterial lesions within murine cardiac 
allografts in the absence of C4d deposition (61). Additionally, Yin et al. reported IgG1-
mediated rejection of cardiac xenografts in mice (62). Interestingly, Rahimi et al. reported 
that cardiac rejection is not induced following the transfer of 25 μg IgG2b nor 100 μg IgG1. 
However, if 25 μg IgG2b and 100 μg IgG1 are co-transferred, rejection occurs (63). These 
results suggest that IgG1 is deleterious to allografts in this model under certain conditions 
and highlight the complexity of humoral alloimmune responses on transplant outcomes. In 
contrast, other reports using a model of renal allograft rejection found that production of 
IgG2a was associated with rejection, whereas IgG1 was associated with tolerance (64). In 
these studies tolerance was transferable by AT of CD4+ T cells, presumably T regulatory 
cells, but it is not clear whether or not AT of IgG1 or IgG2a alloantibodies was protective or 
deleterious.
Our data with CD8-depleted MHC class II KO recipient mice indicate that NKT cells and B 
cells alone are not sufficient for alloantibody production under physiological conditions 
posttransplant. Experiments using mixed bone marrow chimeras are currently in progress to 
directly examine whether cognate interactions between NKT cells and B cells facilitate 
alloantibody production. It is somewhat surprising that IFN-γ, not IL-4 (both dominant 
NKT-produced cytokines), is required by NKT cells to enhance IgG1 alloantibody 
production in vivo. However, it is possible that these results could be explained by previous 
reports which indicate that IFN-γ can induce IL-18 (65), a pleiotropic cytokine, capable of 
inducing Th2 cytokines, including IL-4 (66, 67). Additionally, IL-4 and IL-4Rα have been 
shown to be unnecessary for the development of NKT effector functions (68).
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We found that the number of IL-4+CD4+ T cells is reduced in CD8-depleted NKT deficient 
recipients compared to CD8-depleted WT recipients which correlates with reduced levels of 
serum alloantibody. One hypothesis to explain these results is that NKT cells might 
“license” DCs to stimulate the maturation of IL-4+CD4+ T cells necessary to stimulate B 
cell production of IgG1 alloantibody. Studies are underway to investigate if NKT cells 
license APCs to stimulate Th2 CD4+ T cell responses, indirectly enhance CD4+ T cell 
activation and/or trafficking, and/or stimulate B cells directly in concert with CD4+ T cell/B 
cell interactions (Figure S3). Many other interesting questions require further investigation 
such as the role of CD1d-dependent cognate interactions and the nature of the ligand in this 
response since glycolipid moieties are known to differ in their APC preference (69) and their 
Th1/Th2 bias (70). Hepatocytes are known to express CD1d and may directly interact with 
type I NKT cells. We are also interested in determining the immune depots where NKT cell 
interactions occur.
In conclusion, the present study highlights a novel and important role for NKT cells in 
posttransplant IgG1 alloantibody production. Human IgG1 antibodies directly correlate with 
human kidney allograft rejection and function (71) and this human isotype is, in part, driven 
by IL-4 (72-76). This would suggest that the mechanisms promoting IgG1 antibody 
production, in mice (IL-4-dependent) and human, may be similar. Studies are ongoing to 
further clarify the mechanisms by which NKT cells promote humoral alloimmunity. The 
results of our current studies predict that interference with NKT mechanisms promoting 
alloantibody production or with type I NKT cells directly is expected to suppress the 
magnitude of posttransplant alloantibody production.
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Figure 1. Type I NKT cells are critical for maximal alloantibody production following allogeneic 
hepatocyte transplant
C57BL/6 (wild-type; WT), CD1d KO, and Jα18 KO mice (H-2b) were transplanted with 
allogeneic FVB/N (H-2q) hepatocytes. Recipients were left untreated or CD8-depleted (day 
−2,−1). Serum was tested for alloantibody on day 14 posttransplant by two methods- A) 
percent allogeneic target splenocytes bound and B) by serum dilution to calculate 
alloantibody titer. Naïve serum and third party B10.BR targets were used as negative 
controls. Both WT (9.7±2.5%; n=13; titer=90±5 n=5) and CD1d KO (11.0±4.5%; n=4; 
titer=66.7±10 n=3) recipients produced similar low, but significant alloantibody levels 
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compared to naïve controls (p<0.05). CD8-depleted WT mice (76.9±3.4%; n=7; 
titer=1800±89 n=5) produced increased alloantibody compared to WT recipients (9.7±2.5%; 
titer=90±5; p<0.0001). CD8-depleted CD1d KO recipients (34.8±4.0%, n=5; titer=333±39 
n=3) produced significantly less alloantibody than CD8-depleted WT recipients (76.9±3.4%, 
p<0.0001; titer=1800±89, p=0.016; as signified by “*” for both). Jα18 KO recipients 
exhibited low alloantibody production (2.0±0.4%, n=5; titer=22±3 n=6). CD8-depleted Jα18 
KO recipients (6.6±2.4%, n=14; titer=22±2 n=6) produced significantly less alloantibody 
than CD8-depleted WT recipients (76.9±5.0%, p<0.001; titer=1800±89, p=0.0041; as 
signified by “†” for both). C) Analysis of alloantibody isotype by titer analysis shows that 
IgG1 is the dominant posttransplant alloantibody isotype with relatively low contributions 
from IgG2b, IgG2c, and IgG3.
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Figure 2. Type I NKT cell-deficient recipients have fewer antibody producing cells
CD8-depleted wild-type (WT) and Jα18 KO mice were transplanted with FVB/N 
hepatocytes. ELISPOT was used to determine the number of antibody producing cells on 
days 4, 8, 11, and 15 posttransplant. A) WT transplant recipients exhibited a significant 
induction of IgG1-producing cells (spot forming cells, SFC) per 106 cells analyzed on days 
8 (288±42) and 11 (266±53) posttransplant, compared to naïve (day 0) WT mice (45±15; 
p<0.0001 for both comparisons). Jα18 KO recipients exhibited significantly fewer IgG1-
producing cells per 106 cells on days 8 (169±28) and 11 (94±30) posttransplant, compared 
to WT recipients (p<0.006 for both comparisons, as signified by “*”). B) In vitro antibody 
production, as demonstrated by a side-by-side ELISA, was lower in Jα18 KO splenocytes 
(day 8= 63.9±17.1, day 11= 58.4±7.2 ng/mL per 106 splenocytes) versus WT splenocytes 
(day 8= 157.2±29.2, day 11= 106.6±22.0 ng/mL per 106 splenocytes; p<0.02 for both days, 
as signified by “†”).The experimental results are representative of duplicate experiments. 
Error bars designate the standard error (based on 4 to 10 wells per data point from 2 mouse 
spleens).
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Figure 3. Type I NKT cell enhanced alloantibody production is IFN-γ-dependent, but IL-4-
independent
Jα18 KO mice (H-2b) were transplanted with allogeneic FVB/N (H-2q) hepatocytes. 
Recipients were left untreated or CD8-depleted (day -2,-1). Type I NKT cells were 
adoptively transferred (AT; 1x106 cells i.v.) into CD8-depleted Jα18 KO mice immediately 
following allogeneic hepatocyte transplant. Serum alloantibody was tested on day 14 by two 
methods- A) percent allogeneic target splenocytes bound and B) by serum dilution to 
calculate alloantibody titer. Naïve serum was used as a negative control. AT of wild-type 
(WT) NKT cells into CD8-depleted Jα18 KO recipients induced significant enhancement of 
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alloantibody production (33.3±1.7%; n=7; titer=142±11 n=6) compared to CD8-depleted 
Jα18 KO recipients (6.6±1.2%, n=14, p<0.0001; titer=22±2, n=6; p<0.0031; as signified by 
“*” for both). Jα18 KO recipients adoptively transferred with IL-4 KO NKT cells 
(27.0±2.1%; n=5; titer=113±16 n=4) produced similar alloantibody levels compared to 
recipients which received AT of WT NKT cells (p=ns). CD8-depleted Jα18 KO recipients 
adoptively transferred with IFN-γ KO NKT cells (4.8±2.3%; n=4; titer=18±1 n=6) produced 
significantly less alloantibody compared to recipients which received AT of WT NKT cells 
(†, p<0.003 for both methods). C) Analysis of alloantibody isotype by titer analysis shows 
that IgG1 is the dominant posttransplant alloantibody isotype with relatively low 
contributions from IgG2b, IgG2c, and IgG3.
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Figure 4. NKT cells enhance maturation of IL-4-producing CD4+ T cells following allogeneic 
hepatocyte transplant
Wild-type (WT) and CD1d KO mice (H-2b) were transplanted with allogeneic FVB/N 
(H-2q) hepatocytes. Recipients were left untreated or CD8-depleted (day -2,-1). On day 7, 
splenocytes were harvested and analyzed for intracellular IFN-γ and IL-4 within CD4+ T 
cells. WT and CD1d KO recipients both exhibited increased percentages of IL-4+CD4+ T 
cells (1.1%±0.3%, n=3 and 1.5%±0.3%, n=3, respectively) compared to naïve controls 
(0.2%±0.0%, n=3; p<0.02 for both). CD8-depleted WT recipients exhibited a greater 
percentage of IL-4+CD4+ T cells (2.6%±0.2%, n=5; p=0.0005, as signified by “*”) 
compared to CD8-sufficient WT recipients. In contrast, IL-4+CD4+ T cells were 
significantly lower in CD8-depleted CD1d KO recipients (1.5%±0.2%, n=5; p=0.0028, as 
signified by “†”) compared to CD8-depleted WT recipients. WT and CD1d KO recipients 
exhibited a significantly greater percentage of IFN-γ+CD4+ T cells (5.0%±0.4%, n=3 and 
5.6%±0.5%, n=3, respectively) compared to naïve controls (0.3%±0.1%, n=3; p<0.01 for 
both). IFN-γ+CD4+ T cells from CD8-deficient WT and CD1d KO recipients were 
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comparable to each other (5.2%±0.4%, n=5 and 4.3%±0.4%, n=5) and their CD8-sufficient 
counterparts.
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